At its meeting on 17 June 2024, the Transparency Council adopted opinion No. 94/2024 on the inclusion in the reimbursement of medicines containing the active substance Amantadine in terms of indications for use or dosage, or route of administration different from those specified in the Summary of Product Characteristics. of the Summary of Product Characteristics, i.e., tardive dyskinesia in adults – treatment of.
Publication on the list of opinions on active substances for off-label indications >>